99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
About this study
This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.
- Condition
- Prostate Carcinoma, Recurrent Prostate Carcinoma
- Tested
- 99mTc-based PSMA Imaging and Surgery Agent, Computed Tomography, Single Photon Emission Computed Tomography
- Sponsor
- Jonsson Comprehensive Cancer Center
Who can join
- Age
- Not specified
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 8
- Eligible sex: Male
- Study condition: Prostate Carcinoma, Recurrent Prostate Carcinoma
- Men with PCa (primary or recurrent disease)
- Men who received a 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) for staging or restaging
- Men with evidence of lymph nodes (LNs)-positive disease on 68Ga-PSMA-11 PET/CT
- Men who are scheduled for pelvic LN dissection (PLND)
- Men who can provide oral and written informed consent
- Men who can comply with study procedures
Exclusion 2
- Patients who started any PCa treatment between study enrollment and surgery
- Technically inaccessible nodal location
Where
1 site, 1 recruiting
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Contact
-
Deepu Varughese
310-206-7372 DVarughese@mednet.ucla.edu
-
Ankush Sachdeva
310-794-3421 ASachdeva@mednet.ucla.edu
Potential match only. Final eligibility is determined by the study team.